Clinical bottom line
Intrahepatic cholestasis of pregnancy (ICP) remains a challenging condition with significant fetal risks, but recent advances in diagnostic thresholds and emerging therapies offer promise for improved management. Updated evidence supports the use of refined total serum bile acid (TSBA) cutoffs to better stratify risk and guide intervention. Ursodeoxycholic acid (UDCA) continues as first-line treatment, while novel agents such as maralixibat are under investigation. Multidisciplinary care and individualized treatment plans remain essential to optimize maternal and fetal outcomes (Manzotti et al., 2021; Horgan et al., 2023).
What the evidence shows
Manzotti et al. (2021) provide new insights into TSBA diagnostic thresholds, suggesting that a cutoff of ≥10 µmol/L improves sensitivity for ICP diagnosis, while higher levels (≥40 µmol/L) correlate with increased risk of adverse perinatal outcomes. This stratification aids in tailoring monitoring and delivery timing.
Blumenfeld et al. (2022) discuss the clinical uncertainty in ICP management, emphasizing the importance of early diagnosis and multidisciplinary approaches to balance maternal symptom relief and fetal risk mitigation.
Horgan et al. (2023) review current management strategies, reaffirming UDCA as the mainstay treatment to reduce maternal pruritus and potentially improve biochemical markers, although its impact on fetal outcomes remains debated.
Ndoutoumou et al. (2026) report on ongoing trials of maralixibat, an ileal bile acid transporter inhibitor, showing promise in reducing serum bile acids and pruritus with a favorable safety profile, potentially expanding therapeutic options.
Mishra et al. (2017) highlight advances in understanding ICP pathophysiology, including genetic predispositions and bile acid metabolism alterations, which underpin evolving diagnostic and treatment paradigms.
Lucangioli et al. (2012) underscore the utility of detailed bile acid profiling beyond total levels to refine diagnosis and monitor treatment response.
Caveats and uncertainty
Optimal TSBA thresholds for diagnosis and intervention remain debated, with variability in laboratory methods and population differences.
The efficacy of UDCA on improving fetal outcomes is not definitively established despite symptomatic benefits.
Long-term safety and efficacy data for novel agents like maralixibat are pending.
ICP diagnosis can be confounded by other hepatic or dermatologic conditions, necessitating careful clinical correlation.
Management strategies must balance risks of preterm delivery against fetal complications related to cholestasis.
How this may change practice
Clinicians should adopt updated TSBA thresholds to improve diagnostic accuracy and risk stratification in suspected ICP.
UDCA remains first-line therapy, but clinicians should counsel patients regarding its benefits and limitations.
Emerging therapies such as maralixibat may become adjunctive options pending trial results.
Enhanced multidisciplinary collaboration involving obstetrics, hepatology, and neonatology is critical for individualized care.
Increased awareness of ICP’s pathophysiology may prompt earlier diagnosis and tailored monitoring protocols.